

I. IN THE CLAIMS:

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-8. (canceled)

9. (currently amended): An isolated monoclonal antibody against a peptide consisting of amino acid residues 375-580 of GPC 3 as set forth in SEQ ID NO: 4, wherein the antibody has a cytotoxic activity in vitro against the cell line ~~[[,]] HepG2 or HuH-7~~ in the presence of complement or peripheral blood mononuclear cells.

10-22. (Canceled)

23. (previously presented): The antibody claimed in claim 9, wherein the cytotoxic activity is ADCC activity.

24. (previously presented): The antibody claimed in claim 9, wherein the cytotoxic activity is CDC activity.

25. (previously presented): The antibody claimed in claim 9 which is a recombinant antibody.

26. (previously presented): The antibody claimed in claim 25, which is a humanized antibody.

27. (currently amended): The humanized antibody claimed in claim 26, wherein the V region is ~~derived~~ obtained from an antibody of a mammal except human and the C region is ~~derived from~~ a C region of a human antibody.

28. (previously presented): The humanized antibody claimed in claim 27, wherein the C region of the H chain is selected from the group consisting of C γ 1, C γ 2, C γ 3 and C γ 4.

29. (previously presented): The humanized antibody claimed in claim 27, wherein the C region of the L chain is C κ or C λ .